Buy EXEL Ahead of a Potential FDA Win — Risk-Weighted Mid-Term Trade
Exelixis (EXEL) is a profitable oncology company trading near $42.67 with solid free cash flow, low leverage and a pipeline catalyst in zanzalintinib. A favorable FDA outcome could push the stock toward the mid-$40s to $50s; the trade below balances upside with a clear stop and a mid-term time horizon tied to a likely near-term regulatory event.